Martin trained at the University of California, Irvine Hospital in family medicine, where he treated patients of all ages with obesity, diabetes, thyroid & hormone disorders, high blood pressure, age-related diseases, chronic pain, and autoimmune conditions
Patients received a 3-week treatment with dulaglutide (1.5 mg) or placebo (0.9% sodium chloride) subcutaneously once weekly and attended an 8-hour evaluation visit during the last treatment week
These treatments reduce hunger, increase fullness, and optimize your bodys natural weight management processes
Approval status is night and day: tirzepatide is FDA-approved (Mounjaro in 2022, Zepbound in 2023), while retatrutide is still working through Phase 3
With adults who take GLP-1 drugs consuming approximately 16% 39% less calories than during non-GLP-1 use 4 , its easy to understand why QSR brands may be panicking about potential revenue loss created by the release of these wonder drugs
Het betekent wel dat stopzetten best doordacht gebeurt, omdat gewicht na stoppen vaak opnieuw stijgt
